Yael Flamand Selected Research

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

1/2024	Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
11/2023	Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium.
1/2023	Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials.
3/2022	Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis.
1/2022	Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration.
1/2022	Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yael Flamand Research Topics

Disease

8	Neoplasms (Cancer) 01/2023 - 11/2014
6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2024 - 01/2022
4	Disease Progression 01/2023 - 11/2014
2	Squamous Cell Carcinoma of Head and Neck 12/2023 - 01/2023
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2023
1	Lymphopenia (Lymphocytopenia) 11/2023
1	Fatigue 11/2023
1	Leukemia 10/2023
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2023
1	Extranodal Extension 01/2023
1	Carcinoma (Carcinomatosis) 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2023
1	Left Ventricular Dysfunction 01/2023
1	Overweight 01/2023
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022
1	Vision Disorders (Hemeralopia) 10/2022
1	Hemorrhage 10/2022
1	Deglutition Disorders (Dysphagia) 10/2022
1	Oropharyngeal Neoplasms 10/2022
1	Disseminated Intravascular Coagulation 10/2022
1	Pleural Effusion (Pleural Effusions) 03/2022
1	Pancreatitis 03/2022
1	Thrombosis (Thrombus) 01/2022
1	Hyperglycemia 01/2022
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022
1	Neutropenia 04/2015
1	Sarcoma (Soft Tissue Sarcoma) 04/2015
1	Anemia 11/2014
1	Thrombocytopenia (Thrombopenia) 11/2014
1	Ewing Sarcoma (Sarcoma, Ewing) 11/2014

Drug/Important Bio-Agent (IBA)

4	Asparaginase (Elspar)FDA Link 01/2024 - 03/2022
1	Bevacizumab (Avastin)FDA Link 12/2023
1	PlatinumIBA 12/2023
1	trametinibIBA 01/2023
1	Sorafenib (BAY 43-9006)FDA Link 01/2023
1	Sunitinib (Sutent)FDA Link 01/2023
1	NucleotidesIBA 01/2023
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023
1	Estrogen Receptor alphaIBA 01/2023
1	TNF Receptor-Associated Factor 3IBA 01/2023
1	Retinaldehyde (Retinal)IBA 10/2022
1	Dacarbazine (DIC)FDA LinkGeneric 10/2022
1	antiarrhythmic peptide (AAP)IBA 03/2022
1	Insulin (Novolin)FDA Link 01/2022
1	Blood Group Antigens (Blood Groups)IBA 01/2022
1	pegaspargase (Oncaspar)FDA Link 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2015
1	Histone Deacetylase InhibitorsIBA 04/2015
1	Histone Deacetylases (Histone Deacetylase)IBA 04/2015
1	abexinostatIBA 04/2015
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2014
1	TabletsIBA 11/2014
1	olaparibIBA 11/2014

Therapy/Procedure

9	Therapeutics 11/2023 - 04/2015
5	Drug Therapy (Chemotherapy) 12/2023 - 11/2014
2	Induction Chemotherapy 10/2022 - 01/2022
1	Blood Component Removal (Apheresis) 11/2023
1	Precision Medicine 01/2023
1	Radiotherapy 10/2022